Although the market for copyright pro-erectile medications is partially pushed by the cost of prescription drugs, this truth could soon adjust. Since the patents for PDE-5i might be expiring before long, it is conceivable that the expense of these drugs may very well be reduced substantially. This in turn may lead to a lowered demand from customers